WO2008152332A1 - Nouveaux 4-héteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine ainsi qu'en cosmétique - Google Patents
Nouveaux 4-héteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine ainsi qu'en cosmétique Download PDFInfo
- Publication number
- WO2008152332A1 WO2008152332A1 PCT/FR2008/050995 FR2008050995W WO2008152332A1 WO 2008152332 A1 WO2008152332 A1 WO 2008152332A1 FR 2008050995 W FR2008050995 W FR 2008050995W WO 2008152332 A1 WO2008152332 A1 WO 2008152332A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thione
- dihydroimidazole
- general formula
- compound
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the invention relates to novel 4-heteroarylimidazole-2-thiones compounds as industrial and useful products. It also relates to their process of preparation and their use, as inhibitors of tyrosinase, in pharmaceutical or cosmetic compositions intended for the treatment or prevention of pigment disorders.
- the pigmentation of the skin results from the synthesis of melanin by dendritic cells, melanocytes.
- Melanocytes contain organelles called melanosomes that transfer melanin into the upper layers of keratinocytes that are then transported to the surface of the skin by differentiation of the epidermis.
- tyrosinase is a key enzyme that catalyzes the first two steps of melanin synthesis. Homozygous tyrosinase mutations cause type I oculocutaneous albinism characterized by a complete absence of melanin synthesis.
- heteroaryl-imidazole-2-thiones derivatives some have been described as having anti-inflammatory properties (S. maeda, M. suzuki, T. Iwasaki, K. Matsumoto, Y. Iwazawa, Chem Pharm.Bull 1984, 32, 7, 2536-2543).
- Patent JP05132422 discloses the use of certain imidazole-2-thiones as a tyrosinase inhibitor. However, no derivative of imidazole-2-thiones substituted at 4 with a heteroaryl is described in this document. No tyrosinase inhibitory activity is shown for 4-heteroaryl-imidazole-2-thione compounds.
- X is an oxygen atom or a sulfur atom
- a C 1 -C 7 alkyl radical a C 3 -C 7 cycloalkyl radical, one of the ring carbon atoms possibly being replaced by an oxygen atom or sulfur atom;
- R1 and R2 which are identical or different, are chosen from:
- a C 1 -C 7 alkyl radical a C 3 -C 7 cycloalkyl radical, one of the ring carbon atoms possibly being replaced by an oxygen or sulfur atom;
- R 1 and R 2 may form a hydrocarbon ring of 5 or 6 carbon atoms, as well as their salts and tautomeric forms.
- the present invention also relates to the use of the compounds of formula (I), their salts or their tautomeric forms for the preparation of a pharmaceutical composition intended for the treatment or prevention of hyperpigmentary disorders.
- salts of the compounds of general formula (I) with a pharmaceutically acceptable acid there may be mentioned preferably the salts with an organic acid or with an inorganic acid.
- Suitable inorganic acids are, for example, hydrohalic acids such as hydrochloric acid or hydrobromic acid, sulfuric acid, nitric acid.
- suitable organic acids are picric acid, methanesulfonic acid, ethanesulfonic acid and trifluoromethanesulfonic acid.
- the compounds of general formula (I) may also exist in the form of hydrates or solvates with water or with a solvent.
- Suitable solvents for forming solvates or hydrates are, for example, alcohols such as ethanol or isopropanol or water.
- heterocyclic radical of the compounds according to the invention of general formula (II):
- C3-C7 cycloalkyl denotes a saturated, cyclic hydrocarbon-based chain comprising from 3 to 7 carbon atoms.
- the C 3 -C 7 cycloalkyl radical is chosen from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl radicals.
- C1-C7 alkyl denotes a saturated hydrocarbon chain, linear or branched, comprising from 1 to 7 carbon atoms.
- the C 1 -C 7 alkyl radical is chosen from methyl, ethyl, propyl, i-propyl, butyl, t-butyl, pentyl, hexyl and heptyl radicals.
- C1-C4 alkyl denotes a saturated hydrocarbon chain, linear or branched, comprising from 1 to 4 carbon atoms.
- the C 1 -C 4 alkyl radical is chosen from methyl, ethyl, propyl, i-propyl, butyl and t-butyl radicals.
- C 4 -C 9 cycloalkylalkyl denotes a saturated hydrocarbon chain, linear or branched, substituted by a cycloalkyl radical and comprising from 4 to 9 carbon atoms.
- the C 4 -C 9 cycloalkylalkyl radical is chosen from cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl and cyclohexylethyl radicals.
- C1-C4 alkoxycarbonyl denotes a carboxy radical substituted by a linear or branched saturated hydrocarbon-based chain containing from 1 to 4 carbon atoms.
- the C1-C4 alkoxycarbonyl radical is chosen from the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and butoxycarbonyl radicals.
- C1-C6 alkoxycarbonyl denotes a carboxy radical substituted by a linear or branched saturated hydrocarbon-based chain comprising from 1 to 6 carbon atoms.
- the C1-C6 alkoxy radical is chosen from methoxy, ethoxy, propoxy, butoxy, pentoxy and hexyloxy radicals.
- the compounds of general formula (I) that are particularly preferred are those for which:
- R1 represents a hydrogen
- R2 represents a C1-C7 alkyl radical or a C3-C7 cycloalkyl radical.
- the compounds of general formula (I) that are particularly preferred are those for which the heterocyclic radical of general formula (II) represents a thiophene of general formula (IIa).
- Step a the commercial heterocycles (1) are acetylated according to the conventional synthesis conditions, for example in the presence of acetic anhydride and phosphoric acid, to yield the methyl ketones (2) (Kotha, S. Kashinath, D. Lahiri Sunoj, RB, Eur J Org Chem 2004, (19), 4003-4013).
- Step b The alpha bromo ketones of the general formula (3)
- methyl ketones (2) are commercially available or can be prepared from methyl ketones (2) according to conventional methods of synthesis, for example by the action of dibroma in a solvent such as dichloromethane (Laufer, S .; Striegel, H. -G .; Neher, K. Zechmeister, P., Donat, C., Stolingwa, K .; Baur, S., Tries, S. Kammermeier, T., Dannhardt, G. Kiefer, W, Arch Pharm 1997, 330 (9), 307; -312)
- a solvent such as dichloromethane
- Step c the alpha bromo ketones (3) are reacted with sodium diformamide for example in acetonitrile (Yinglin, H. Hongwen, H. Synthesis, 1990, 615) to give after hydrolysis of the reaction crude with acid hydrochloric acid for example (Ying-Lin, H., Hong-Wen, HH, Tetrahedron Lett, 1989, 30, 5285) hydrochlorides of acyl amines of general formula (4).
- Step d a cyclization reaction of the compounds of general formula (4) with potassium thiocyanate makes it possible to obtain the imidazole-2-thiones of general formula (I) (Mor, M .; Bordi, F .; Silva, C, Rivara, S., Crivori, P., Plazzi, PV, Ballabeni, V., Caretta, A., Barocelli, E., Impicciatore, Carrupt, P., A., Testa, BJ Med. Chem 1997; 40 (16); 2571-2578.)
- the compounds of the present invention have a value of IC 50 (dose inhibiting 50% of the enzymatic activity) with respect to tyrosinase less than or equal to 10 ⁇ M and more particularly less than or equal to 1 ⁇ M .
- the invention therefore relates to the use of at least one compound of general formula (I) as defined above for the preparation of a pharmaceutical or cosmetic composition in which said compound has a tyrosinase inhibitory activity.
- the invention also relates to a product chosen from compounds of formula (I) for its use in the treatment and / or prevention of pigment disorders.
- the invention also relates to a method of therapeutic or cosmetic treatment, comprising the administration of a pharmaceutical or cosmetic composition comprising said compound, as a tyrosinase inhibitor.
- the invention also relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of pigment disorders, especially hyperpigmentary disorders.
- the compounds used according to the invention are particularly suitable for the treatment and the prevention of pigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, irregular hyperpigmentations related to photo aging, freckles, post inflammatory hyperpigmentations due to abrasion or burn or scarring or dermatitis or contact allergy, Nevis, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or medicinal origin, melanomas or any other hyperpigmentary lesion.
- pigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, irregular hyperpigmentations related to photo aging, freckles, post inflammatory hyperpigmentations due to abrasion or burn or scarring or dermatitis or contact allergy, Nevis, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or medicinal origin, melanomas or any other hyperpigmentary lesion.
- the subject of the present invention is also a pharmaceutical composition intended in particular for the treatment of the abovementioned conditions, which comprises, in a pharmaceutically acceptable carrier and compatible with the mode of administration chosen for the latter, at least one compound of general formula (I) under one of its tautomeric forms, or a salt thereof with a pharmaceutically acceptable acid.
- pharmaceutically acceptable carrier is meant a medium compatible with the skin, mucous membranes and integuments.
- composition according to the invention can be carried out topically.
- the pharmaceutical composition is packaged in a form suitable for topical application. Topically, it is meant to be administered on the skin or mucous membranes.
- the pharmaceutical composition according to the invention is more particularly intended for the treatment of the skin and mucous membranes and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks , ointments, powders, soaked swabs, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos, or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric or gelled patches allowing controlled release.
- the compositions used for a topical application have a concentration of compound according to the invention generally between 0.001% and 10% by weight, preferably between 0.01% and 5% by weight, relative to the total weight of the composition. .
- the compounds of general formula (I) according to the invention also find application in the cosmetics field, in particular in the protection against the harmful aspects of the sun, for preventing and / or for combating photo-induced or chronological aging of the skin. skin and integuments.
- the invention therefore also relates to a cosmetic composition
- a cosmetic composition comprising, in a cosmetically acceptable support, at least one compound of general formula (I).
- cosmetically acceptable carrier is meant a medium compatible with the skin, mucous membranes and integuments.
- the subject of the invention is also the cosmetic use of a compound of formula (I) or of a composition comprising at least one compound of general formula (I) for preventing and / or treating the signs of skin aging.
- the subject of the invention is also the cosmetic use of a compound of formula (I) or of a composition comprising at least one compound of general formula (I) for body or hair hygiene.
- the cosmetic composition according to the invention containing, in a cosmetically acceptable support, a compound of general formula (I), or one of its tautomeric forms or a salt thereof with a pharmaceutically acceptable acid, can in particular be in the form of a cream, a milk, a gel, suspensions of microspheres or nanospheres or lipid or polymeric vesicles, soaked swabs, solutions, sprays, foams, sticks, soaps, washing bases or shampoos.
- the concentration of compound of general formula (I) in the cosmetic composition is preferably between 0.001% and 3% by weight, relative to the total weight of the composition.
- the pharmaceutical and cosmetic compositions as described above may also contain inert additives, or even pharmacodynamically active additives for pharmaceutical compositions, or combinations of these additives, and in particular:
- UV-A and UV-B filters antioxidants, such as ⁇ -tocopherol, butylhydroxyanisole or butylhydroxytoluene, superoxide dismutase, ubiquinol;
- moisturizing agents such as glycerol, PEG 400, thiamorpholinone, and its derivatives or urea; antiseborrhoeic or antiacne agents, such as S-carboxymethylcysteine, S-benzylcysteamine, their salts or their derivatives, or benzoyl peroxide.
- the residue is filtered on a silica eluting patch: 20% ethyl acetate and 80% heptane. 8 g of a brown oil are obtained.
- the preceding oil is dissolved in 24 mL of tetrahydrofuran and cooled to 0 ° C. 0.84 mL of diethyl phosphite and 0.92 mL of thethylamine are added to the reaction mixture. The mixture is stirred for 1 hour at 0 ° C. and then for 4 hours at room temperature.
- the reaction medium is poured into 200 ml of ice-water and then extracted with 200 ml of ethyl acetate.
- Example 3 4- (5-methylthiophen-2-yl) -1,3-dihydroimidazole-2-thione 1 H NMR (DMSO 400 MHz.): 2.41 (s, 3H, CH 3); 6.72 (s, 1H, CH); 6.91 (s, 1H, CH);
- Inhibitor activity is measured from a B16F1 cell lysate (murine melanoma line).
- the tyrosinase present in these cells catalyzes the hydroxylation of L-tyrosine to L-DOPA and then the oxidation of L-DOPA to dopaquinone.
- MBTH 3-methyl-2-benzothiazolinone hydrazone
- dopaquinone is trapped to form a pink complex which absorbs at 520 nm.
- the B16F1 cells are cultured in DMEM medium + 10% fetal calf serum + 10 -9 M ⁇ MSH for 4 days at 37 ° C. under 7% CO 2 .
- the plate is incubated at 37 ° C. and a spectrophotometric reading is carried out at 520 nm after 6 hours of incubation. To overcome any absorption of the products, one works in corrected absorbance (absorbance at time 6h - absorbance at time zero).
- Inhibitors are tested in dose response to calculate an IC50 (inhibiting dose
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010510857A JP2010529097A (ja) | 2007-06-05 | 2008-06-04 | チロシナーゼ阻害剤としての新規の4−ヘテロアリールイミダゾール−2−チオン、その調製方法ならびにヒトの医薬および化粧品におけるその使用 |
MX2009012714A MX2009012714A (es) | 2007-06-05 | 2008-06-04 | Nuevas 4-heteroail-imidazol-2-tionas como inhibidores de la tirosinasa, su procedimiento de preparacion y su uso en medicina humana asi como en cosmetica. |
EP08805935A EP2164845A1 (fr) | 2007-06-05 | 2008-06-04 | Nouveaux 4-héteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine ainsi qu'en cosmétique |
CA002688237A CA2688237A1 (fr) | 2007-06-05 | 2008-06-04 | Nouveaux 4-heteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique |
CN200880018930A CN101679388A (zh) | 2007-06-05 | 2008-06-04 | 用作酪氨酸酶抑制剂的新型4-杂芳基咪唑-2-硫酮、它们的制备方法和它们在人类药物和化妆品中的用途 |
AU2008263667A AU2008263667A1 (en) | 2007-06-05 | 2008-06-04 | Novel 4-heteroaryl-imidazole-2-thiones used as tyrosinase inhibitors, method for preparing same and use thereof in human medicine and cosmetology |
US12/631,309 US7989483B2 (en) | 2007-06-05 | 2009-12-04 | 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0755473 | 2007-06-05 | ||
FR0755473A FR2917089B1 (fr) | 2007-06-05 | 2007-06-05 | Nouveaux 4-heteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique. |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/631,309 Continuation US7989483B2 (en) | 2007-06-05 | 2009-12-04 | 4-heteroarylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008152332A1 true WO2008152332A1 (fr) | 2008-12-18 |
Family
ID=38962668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2008/050995 WO2008152332A1 (fr) | 2007-06-05 | 2008-06-04 | Nouveaux 4-héteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine ainsi qu'en cosmétique |
Country Status (12)
Country | Link |
---|---|
US (1) | US7989483B2 (fr) |
EP (1) | EP2164845A1 (fr) |
JP (1) | JP2010529097A (fr) |
KR (1) | KR20100028090A (fr) |
CN (1) | CN101679388A (fr) |
AR (1) | AR066871A1 (fr) |
AU (1) | AU2008263667A1 (fr) |
CA (1) | CA2688237A1 (fr) |
FR (1) | FR2917089B1 (fr) |
MX (1) | MX2009012714A (fr) |
RU (1) | RU2009149608A (fr) |
WO (1) | WO2008152332A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010529096A (ja) * | 2007-06-05 | 2010-08-26 | ガルデルマ・リサーチ・アンド・デヴェロップメント | チロシナーゼ阻害剤として使用される新規の4−フェニルイミダゾール−2−チオン、その調製方法ならびにヒトの医学および化粧品学におけるその使用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI508950B (zh) * | 2014-08-29 | 2015-11-21 | Univ Hungkuang | 3-methyl-2-sulfanyl-2,3-dihydro-1H-imidazole-1-carboxylic acid Tertiary butyl ester and its preparation method and use |
JP6553961B2 (ja) * | 2015-06-25 | 2019-07-31 | 花王株式会社 | 美白剤 |
CN116854267B (zh) * | 2023-09-01 | 2024-01-02 | 杭州尚善若水环保科技有限公司 | 一种用于反渗透膜的阻垢剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05124923A (ja) * | 1991-04-09 | 1993-05-21 | Sansho Seiyaku Co Ltd | メラニン生成抑制外用剤 |
JPH05132422A (ja) * | 1991-04-09 | 1993-05-28 | Sansho Seiyaku Co Ltd | メラニン生成抑制外用剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4159338A (en) * | 1977-02-09 | 1979-06-26 | E. I. Du Pont De Nemours And Company | Antiinflammatory-4,5-dicyclic-2-(substituted thio)-imidazoles and their corresponding sulfoxides and sulfones |
US7115748B2 (en) * | 2004-12-07 | 2006-10-03 | Allergan, Inc. | Method of making imidazole-2-thiones |
FR2917087B1 (fr) * | 2007-06-05 | 2012-09-21 | Galderma Res & Dev | Nouveaux 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique. |
-
2007
- 2007-06-05 FR FR0755473A patent/FR2917089B1/fr not_active Expired - Fee Related
-
2008
- 2008-06-04 CN CN200880018930A patent/CN101679388A/zh active Pending
- 2008-06-04 WO PCT/FR2008/050995 patent/WO2008152332A1/fr active Application Filing
- 2008-06-04 AU AU2008263667A patent/AU2008263667A1/en not_active Abandoned
- 2008-06-04 KR KR1020107000023A patent/KR20100028090A/ko not_active Application Discontinuation
- 2008-06-04 RU RU2009149608/04A patent/RU2009149608A/ru not_active Application Discontinuation
- 2008-06-04 CA CA002688237A patent/CA2688237A1/fr not_active Abandoned
- 2008-06-04 JP JP2010510857A patent/JP2010529097A/ja active Pending
- 2008-06-04 EP EP08805935A patent/EP2164845A1/fr not_active Withdrawn
- 2008-06-04 MX MX2009012714A patent/MX2009012714A/es active IP Right Grant
- 2008-06-05 AR ARP080102387A patent/AR066871A1/es unknown
-
2009
- 2009-12-04 US US12/631,309 patent/US7989483B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05124923A (ja) * | 1991-04-09 | 1993-05-21 | Sansho Seiyaku Co Ltd | メラニン生成抑制外用剤 |
JPH05132422A (ja) * | 1991-04-09 | 1993-05-28 | Sansho Seiyaku Co Ltd | メラニン生成抑制外用剤 |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 199325, Derwent World Patents Index; AN 1993-200406, XP002467531 * |
DATABASE WPI Week 199326, Derwent World Patents Index; AN 1993-208825, XP002467530 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010529096A (ja) * | 2007-06-05 | 2010-08-26 | ガルデルマ・リサーチ・アンド・デヴェロップメント | チロシナーゼ阻害剤として使用される新規の4−フェニルイミダゾール−2−チオン、その調製方法ならびにヒトの医学および化粧品学におけるその使用 |
Also Published As
Publication number | Publication date |
---|---|
MX2009012714A (es) | 2009-12-08 |
CN101679388A (zh) | 2010-03-24 |
KR20100028090A (ko) | 2010-03-11 |
US7989483B2 (en) | 2011-08-02 |
EP2164845A1 (fr) | 2010-03-24 |
AU2008263667A1 (en) | 2008-12-18 |
RU2009149608A (ru) | 2011-07-20 |
CA2688237A1 (fr) | 2008-12-18 |
FR2917089A1 (fr) | 2008-12-12 |
JP2010529097A (ja) | 2010-08-26 |
US20100144813A1 (en) | 2010-06-10 |
FR2917089B1 (fr) | 2009-07-17 |
AR066871A1 (es) | 2009-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1302460B1 (fr) | Composés indole-carboxyliques et leur utilisation comme composés pharmaceutiques | |
FR2939135A1 (fr) | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
FR2939136A1 (fr) | Nouveaux composes 4-(heterocycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
WO2008152332A1 (fr) | Nouveaux 4-héteroaryl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine ainsi qu'en cosmétique | |
EP1878470B1 (fr) | Procédé de dépigmentation de la peau | |
FR2981933A1 (fr) | Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
WO2008152331A9 (fr) | Nouveaux 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, leur procédé de préparation et leur utilisation en médecine humaine ainsi qu'en cosmétique | |
FR2946341A1 (fr) | Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. | |
WO2006103345A1 (fr) | Inhibiteurs de la tyrosinase et leur utilisation pour traiter les desordres hyperpigmentaires | |
FR2884250A1 (fr) | Utilisation des aurones pour leur activite depigmentante ou inhibitrice de la melanogenese dans des compositions cosmetiques ou dermatologiques | |
FR2886844A1 (fr) | Utilisation de composes 2-oxy-acetamide pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/ou leur blanchiment | |
FR2953834A1 (fr) | Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
EP2164486A2 (fr) | Utilisation de 4-phenyl-imidazole-2-thiones comme inhibiteurs de la tyrosinase, pour la préparation de compositions pharmaceutiques ou cosmétiques destinées au traitement ou à la prévention des désordres pigmentaires | |
FR2903694A1 (fr) | Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
FR2890070A1 (fr) | Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
US20100010049A1 (en) | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | |
FR2883875A1 (fr) | Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
FR2883745A1 (fr) | Nouveaux inhibiteurs de la tyrosinase et leur utilisation en medecine humaine ainsi qu'en cosmetique | |
WO2007039821A2 (fr) | Nouveaux inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine et dans des cosmetiques | |
FR2913422A1 (fr) | Procede de traitement cosmetique employant des analogues d'ascorbigene, compositions cosmetiques et composes | |
FR2920771A1 (fr) | Nouveaux derives de phenylurees, inhibiteurs de l'enzymes soat-1, compositions pharmaceutiques et cosmetiques les contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880018930.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08805935 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008805935 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/012714 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2688237 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2231/MUMNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010510857 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008263667 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20107000023 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2008263667 Country of ref document: AU Date of ref document: 20080604 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009149608 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0811352 Country of ref document: BR Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE A PROCURACAO APRESENTADA NAO POSSUI DATA. |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0811352 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI 2320 DE 23/06/2015 |